The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | The potential of iberdomide to enhance CAR T-cell expansion and functionality in multiple myeloma
Samir Parekh, MD, Icahn School of Medicine, Mount Sinai, New York City, NY, discusses the potential of iberdomide to enhance CAR T-cell expansion and functionality in multiple myeloma. This research is being explored in clinical trials to benefit patients receiving idecabtagene vicleucel (ide-cel) or ciltacabtagene autoleucel (cilta-cel). This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The other exciting talk I wanted to highlight from our group is by Adolfo Aleman and Michael Amatangelo who have been working together. Michael from BMS showed that the use of iberdomide, a novel CELMoD that we have worked on in both clinical trials and translational research for several years, can activate T and NK cells. And we use this information to actually prime and further improve the activation of CAR T-cells...
The other exciting talk I wanted to highlight from our group is by Adolfo Aleman and Michael Amatangelo who have been working together. Michael from BMS showed that the use of iberdomide, a novel CELMoD that we have worked on in both clinical trials and translational research for several years, can activate T and NK cells. And we use this information to actually prime and further improve the activation of CAR T-cells. And we have now data showing that this can robustly improve the survival of the CAR T’s, the function of the CAR-T’s, and are designing clinical trials to take advantage of this finding that should help CAR-T patients receiving both ide-cel and cilta-cel.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Disclosures: Grail, Regeneron (ends 9/3/2025), Genentech/ Roche, Poseida Theraputics, Astra-Zeneca, Karyopharm Therapeutics, Celgene/BMS Corporation, Caribou, imCORE.
